Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.
Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R, Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S, Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT. Purcell JW, et al. Among authors: chao dt. Cancer Res. 2018 Jul 15;78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. Epub 2018 May 15. Cancer Res. 2018. PMID: 29764866
Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.
Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH, Evangelista F, Grove J, Cardenas M, James M, Hsi ED, Chao DT, Powers DB, Ramakrishnan V, Dubridge R. Culp PA, et al. Among authors: chao dt. Clin Cancer Res. 2010 Jan 15;16(2):497-508. doi: 10.1158/1078-0432.CCR-09-1929. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068083
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity.
Ho SK, Xu Z, Thakur A, Fox M, Tan SS, DiGiammarino E, Zhou L, Sho M, Cairns B, Zhao V, Xiong M, Samayoa J, Forsyth CM, Powers DB, Chao DT, Hollenbaugh D, Alvarez HM, Akamatsu Y. Ho SK, et al. Among authors: chao dt. Mol Cancer Ther. 2020 Apr;19(4):1040-1051. doi: 10.1158/1535-7163.MCT-19-0608. Epub 2020 Jan 23. Mol Cancer Ther. 2020. PMID: 31974274
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, Cassier PA, Khasraw M, Kindler HL, Fang H, Fan F, Allaire K, Patel M, Ye S, Chao DT, Henner WR, Hayflick JS, McDevitt MA, Fong L. Luke JJ, et al. Among authors: chao dt. J Immunother Cancer. 2021 Feb;9(2):e002015. doi: 10.1136/jitc-2020-002015. J Immunother Cancer. 2021. PMID: 33608377 Free PMC article. Clinical Trial.
34 results